Proportions and Rates of LDA/sustained LDA by Treatment Group
| csDMARD-IR ptsa | bDMARD-IR ptsb | |||||||
|---|---|---|---|---|---|---|---|---|
| Pts achieving CDAI ≤10 | PBO | Bari 2 mg | Bari 4 mg | PBO | Bari 2 mg | Bari 4 mg | ||
| Time | # of visits | Category | N=228 | N=229 | N=227 | N=176 | N=174 | N=177 |
| Original study (24 wks) | ≥1 | % | 44.7 | 60.7 | 65.6 | 26.7 | 39.7 | 48.6 |
| i-rate | 12.06 | 18.79 | 21.50 | 6.36 | 10.08 | 13.38 | ||
| ≥2 | % | 32.0 | 48.5 | 52.9 | 15.9 | 28.7 | 35.6 | |
| i-rate | 7.32 | 12.11 | 13.95 | 3.50 | 6.42 | 8.29 | ||
| Original study + LTE | ≥1 | % | 56.6 | 70.7 | 71.4 | 39.8 | 47.7 | 53.1 |
| i-rate | 4.93 | 8.14 | 9.40 | 2.85 | 3.81 | 4.85 | ||
| ≥2 | % | 48.2 | 61.6 | 61.2 | 27.8 | 39.1 | 44.1 | |
| i-rate | 3.41 | 5.33 | 5.78 | 1.66 | 2.57 | 3.13 | ||
Pts were defined as responders if they met the response criterion within the stated time frame, prior to any rescue or discontinuation. % = percent of pts meeting response criteria; ≥2 = at least 2 consecutive visits with CDAI ≤10; i-rate = exposure-adjusted incidence rate (% pts/month); N = number of randomised and treated pts; PBO = placebo treated pts in original study, Bari 4 mg treated pts in LTE. aRA-BUILD, bRA-BEACON.